Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 1,379

Document Document Title
WO/2007/076163A3
The present disclosure concerns a process for removing steryl glycosides or monoacylglycerols from biodiesel by contact of the biodiesel with an absorbant, or filter aid. Treated biodiesel as well as steryl glycosides derived from biodie...  
WO/2008/028584A1
The invention relates to preparations for oral administration, containing (a) physiologically active fatty acids with 16 to 26 carbon atoms and 2 to 6 double bonds, the esters or glycerides thereof and (b) Hoodia extracts or the steroid ...  
WO/2008/026300A1
The object is to provide a novel therapeutic agent for malignant tumor. Disclosed is a therapeutic agent for malignant tumor or an apoptosis inducer which comprises a compound selected from epoxyazadiradione, gedunin, 17-epi-17-hydroxyaz...  
WO/2007/089688A3
This process relates to a pharmaceutical composition of an Na-K- ATPase ligand which will stimulate Na/K-ATPase signaling in a pharmaceutically acceptable vehicle. In one embodiment, the composition may be used to treat a skin disorder. ...  
WO/2008/022875A1
Process for preparing a composition comprising one or more steroidal glycosides, comprising the steps of: (a) harvesting Hoodia plants, (b) cutting up the harvested plants, (c) drying the cut plants, whereby exposure to UV light during t...  
WO/2007/070598A9
The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in...  
WO/2007/112573A1
The present invention describes nitrate esters of sterols and stanols that bear an ascrobic acid moiety and a phosphate linking group, as well as pharmaceutically acceptable salts and stereoisomers thereof The invention also provides nov...  
WO/2007/115187A2
A platform service that is used by an application may be linked to an advertising service. A cost of using the platform service may be reduced based on the linking.  
WO/2007/060206A3
New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here de...  
WO/2007/094166A1
A drug for recovery from a spinal cord injury, characterized by containing as an active ingredient a compound represented by the following structural formula (1) or a pharmaceutically acceptable salt thereof: Structural formula 1 (wherei...  
WO/2006/124012A3
The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions an...  
WO/2007/080951A1
The invention provides a novel process for the production of steroids, namely, a process for the production of 5β-3,7 -dioxocholanoic acid or ester derivatives thereof which comprises using as the raw material a sterol having double bon...  
WO2007016656A8
Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor- 1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigen...  
WO/2007/076163A2
The present disclosure concerns a process for removing steryl glycosides or monoacylglycerols from biodiesel by contact of the biodiesel with an absorbant, or filter aid. Treated biodiesel as well as steryl glycosides derived from biodie...  
WO/2007/070598A2
The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in...  
WO/2006/113495A3
The present invention relates to a series of dicarboxylic acid ester derivatives of ginsenosides such as succinate and glutarate derivatives of 20-O-β-D- glucopyranosyl-protopanaxadiol (compound K, abbreviated as CK), preparation thereo...  
WO/2007/016656A3
Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor- 1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigen...  
WO/2007/060206A2
New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here de...  
WO/2005/123959A3
High density multiplexing assays for proteins, nucleic acids, and other molecules are described based upon using mass spectrometry detection. A solid-state support assay format is utilized, whereby, the bead carries both a coding molecul...  
WO/2007/056326A2
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length a...  
WO/2007/043302A1
Disclosed is a pharmaceutical or beverage/food which can inhibit the production of an adipocytokine, particularly an adipocytokine that can induce the resistance to insulin, to thereby prevent or ameliorate the occurrence of a morbid con...  
WO/2007/043305A1
Disclosed is a pharmaceutical or beverage/food which can inhibit the production of an adipocytokine, particularly an adipocytokine that can induce the resistance to insulin, to thereby prevent or ameliorate the occurrence of a morbid con...  
WO/2007/039346A2
A photoresist composition including a polymer, a photoacid generator and a dissolution modification agent, a method of forming an image using the photoresist composition and the dissolution modification agent composition. The dissolution...  
WO/2007/034851A1
Disclosed is a pharmaceutical or beverage/food which can reduce the fat accumulated in the abdominal cavity and can prevent or ameliorate visceral obesity which is believed to be the primary cause of metabolic syndrome. The pharmaceutica...  
WO/2007/006208A1
Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and...  
WO/2006/124012A2
The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions an...  
WO/2006/123464A1
Use of 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol or compositions which consist of extracts of liliaceous plants or fractions thereof containing 3-O-β-D-glucopyranosyl-4-methyl- ergost-7-en-3-ol and contain the compound in amounts...  
WO/2006/113495A2
The present invention relates to a series of dicarboxylic acid ester derivatives of ginsenosides such as succinate and glutarate derivatives of 20-O-β-D- glucopyranosyl-protopanaxadiol (compound K, abbreviated as CK), preparation thereo...  
WO/2006/110810A2
The present invention relates to crystalline polymorphs of 3-O-(3',3'-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt ("DSB•2NMG)"), pharmaceutical compositions of the same and use of the same as an active pharmaceutical a...  
WO/2006/086377A2
The invention relates to a multiplex real-time RT-PCR assay with a heterologous internal control system (i.e., EGFP-RNA) for the simple and fast diagnosis of classical swine fever virus (CSFV). Primers and FAM-labeled TaqMan probes, spec...  
WO2006019685A3
The present invention provides novel ginsenoside compounds, compositions (e.g. pharmaceutical compositions) comprising the ginsenoside compounds, and methods for the synthesis of these ginsenoside compounds. Additionally, the present inv...  
WO/2006/052717A2
A glucuronide metabolite of tigecycline, and its corresponding epimer, have been identified in humans treated with tigecycline. Mass spectral data have been used to identify these structures.  
WO/2006/045171A2
The present invention refers to a process to obtain ergostane derivative dry steroids, such as physalins, including steps of: (a) grinding of dried parts of plant (s) from the Solanaceae species; (b) treatment of the said plant (s)' part...  
WO/2006/019685A2
The present invention provides novel ginsenoside compounds, compositions (e.g. pharmaceutical compositions) comprising the ginsenoside compounds, and methods for the synthesis of these ginsenoside compounds. Additionally, the present inv...  
WO2004028475A3
Glycosylceramide analogues are disclosed in which the ceramide moiety and optionally the carbohydrate moiety are modified or replaced. These analogues are useful as immunomodulators, antitumor agents, and as other pharmaceutical agents.  
WO/2005/116042A1
The present invention relates to ginsenoside derivatives effective in prevention and treatment of cancer. More specifically, the present invention relates to ginsenoside derivatives with novel structures effective in prevention and treat...  
WO/2005/116049A1
A method for selectively separating desirable steroidal glycosides from undesirable components present in plant material of the Asclepiadaceae family containing the same. The method comprises contacting the plant material or material der...  
WO/2005/095436A1
3-O-β-D-Glucopyranosyl-4-methylerogst-7-en-3-ol or an extract of a liliaceae plant or a fraction thereof containing this compound, which is a composition containing 0.001% by mass or more of the above compound, is used as the active ing...  
WO/2005/084689A1
The invention discloses a Radix astragli extract and production method and use thereof. Such Radix astragli extract mainly comprises astragalus saponin, organic acid and astragalus flavonoid glycoside. Such production method consists of ...  
WO2004024745A3
There is provided a crystalline chemical complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in the crystalline complex is of space group P212121 havi...  
WO2004017904A3
The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous...  
WO/2005/042033A1
The present invention is directed to novel chemical agents for compounds and their use for imaging myocardial perfusion. The invention also is directed to a kit for forming such novel agents. The chemical agents for the present invention...  
WO/2005/040189A1
This invention relates to a group of novel dammarane sapogenin compounds and their use in anti-cancer applications. More particularly, this invention pertains to a novel group of dammarane sapogenin: PPD derivative 1, 2, 3, 4 and PPT der...  
WO2004005313A3
The present invention relates (a) to new compounds represented by Formula I wherein M represents a macrocode subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, V represents an...  
WO2004098538A3
The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the inventi...  
WO2004092329A3
The present invention discloses novel saponin derivatives for use with nucleic acids that induce an immune response when administered to animals and humans. The novel saponin derivatives disclosed comprise (a) a saponin aglycone core, wh...  
WO/2005/007172A1
A medical preparation which can maximize the effect of a cholestanol glycoside useful as an antitumor agent. It is a liposome which comprises: a hydrophobic-compound glycoside having an antitumor activity, having GlcNAc-Gal-, GlcNAc-Gal-...  
WO/2004/098538A2
The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the inventi...  
WO/2004/092329A2
The present invention discloses novel saponin derivatives for use with nucleic acids that induce an immune response when administered to animals and humans. The novel saponin derivatives disclosed comprise (a) a saponin aglycone core, wh...  
WO/2004/058796A1
There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng sa...  

Matches 101 - 150 out of 1,379